RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively.
Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Stocks youve viewed will appear in this box, letting you easily return to quotes youve seen previously.
It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company.
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares. Descargue fotos de Rap de stock Gran banco de imgenes libres de derechos Millones de fotos sin royalties de la mejor calidad a precios asequibles. RAPT Therapeutics (NASDAQ:RAPT) Intraday Stock Chart Thursday 13 January 2022 Your Recent History LSE. RAPT Therapeutics General Information Description.